Even though there are many known causes of delay, some children will never receive a diagnosis. Investigation
Developmental monitoring is performed during wellness visits to check a childs development. Health authorities encourage parents to monitor their childs development, the CDCs program "Learn the Signs. Act Early" provides materials for a childs development is assessed based on expected milestones for actions like how they play, learn, speak, act and move. Missed milestones may be cause for concern, so the doctor or another specialist may call for a more thorough test or exam to take a closer look, this is usually done by going through Developmental Screening. Developmental Screening is a more involved process. The evaluating professional will ask a parent to complete a research-based questionnaire that asks about a childs development, including language, movement, thinking, behavior, and emotions. Developmental Screening is recommended by the American Academy of Pediatrics (AAP) to all children at 9, 18, and 30 months. The AAP also recommends that all children be screened specifically for autism spectrum disorder (ASD) during regular well-child visits at 18 and 24 months. If a Developmental Screening indicates a delay, the child should then be assessed with a Developmental Evaluation. Developmental Evaluations are performed by a Developmental pediatrician, child psychologist, or other trained provider with the purpose of Identifying and diagnosing developmental delays and conditions. Chromosome microarray and karyotyping to look for trisomy, microdeletions, and duplications.
proliferation) and survival of cells and is abnormally activated in, and appears to contribute to the development and or progression of, a wide range of tumors. While further studies are needed, these findings suggest that the cited mutations lead to stimulation of the PI3K/AKT/mTOR pathway and thereby promote the development and/or progression of anogenital papillary hidradenoma in the majority of cases. These abnormalities have not yet been reported in ectopic papillary hidradenomas. Diagnosis
The diagnosis of anogenital papillary hidradenoma lesions, while often suggested based on their clinical presentations, must be differentiated from a wide range of other similarly presenting anogenital lesions such as hemorrhoidal disease, anorectal abscesses, virus-related wart-like lesions, sebaceous cysts, mucous cysts, lipomas, neurofibromas, metastatic carcinomas with papillary histopathology, syringocystoadenocarcinoma papilliferum (i.e. malignant syringocystadenoma papilliferum), syringocystadenoma papilliferum, melanomas, eccrine porocarcinomas, squamous cell carcinomas, nodular lesions in extramammary Paget disease, dermatofibroma, focal areas of mucinosis, colloid milium, and sebaceous adenomas. This differentiation is made by finding that a lesion has the histopathological features typical of papillary hidradenomas. However, some cases diagnosed as ectopic papillary hidradenomas, particularly those occurring in men, have subsequently been found to be syringocystadenoma papilliferums or trichoepitheliomas. Further studies are required to better define the criteria for ectopic papillary hidradenomas. Treatment and prognosis
The treatment of choice for anogenital and ectopic papillary hidradenomas, regardless of their locations, is similar: resection of the tumor while preserving the surrounding structures. Recurrence of these tumors is rare and usually due to incomplete removal of the primary lesion.